Skip to search formSkip to main contentSkip to account menu

SR 121463

Known as: SR-121463 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

satavaptan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2006
Review
2006
Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia.
2006
2006
Synthesis of Arginine Vasopressin V_2 Receptor Antagonist SR-121463
5'-Ethoxy-4-[2-(4-morpholino)ethoxy]spiro[cyclohexane-1,3'-indolin]-2'-one(2)and4-t-butylcarbamoyl-2-methoxybenzenesulfonyl… 
2004
2004
Evidence for a role of protein kinase C- in urine concentration
Yao, Lijun, Dan-Yang Huang, Imke L. Pfaff, Xin Nie, Michael Leitges, and Volker Vallon. Evidence for a role of protein kinase Cin… 
2001
2001
Chemical development of the vasopressin receptor 2 antagonist SR-121463
Abstract A facile convergent total synthesis of the selective, potent, and orally active V2 non-peptide antagonist, SR-121463… 
Review
2001
Review
2001
SR-121463. Sanofi-Synthélabo.
Sanofi-Synthélabo (formerly Sanofi) is developing SR-121463, a vasopressin V, receptor antagonist, as a potential treatment for… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)